,i #aaeth ,,congress #b;d ,session ,h4 ,r4 #gcbd ,,in ,,the ,,house ,,of ,,representatives ,december #ag1 #bjah,mr4 ,kelly of ,pennsylvania introduced the following bill2 which was referred to the ,committee on ,ways and ,means1 and in addition to the ,committee on ,energy and ,commerce1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,preserving ,access to ,orphan ,drugs ,act of #bjah4 #b4 ,clarification of orphan drug exception to annual fee on branded prescription pharmaceutical manufacturers and importers 7a7 ,in general ,section #ijjh7;e77#c7 of the ,patient ,protection and ,affordable ,care ,act is amended to read as follows3 7#c7 ,exclusion of orphan drug sales 7,a7 ,in general ,the term branded prescription drug sales shall not include sales of any drug or biological product-- 7i7 with respect to which a credit was allowed for any taxable year under section #de;,c of the ,internal ,revenue ,code of #aihf1 7ii7 with respect to which a credit was allowable for any taxable year beginning before ,january #a1 #bjaa1 under such section #de;,c 7without regard to whether such credit was claimed or received71 or 7iii7 which was any drug or biological product approved or licensed prior to ,january #a1 #bjaa1 by the ,food and ,drug ,administration1 for marketing solely for #a or more rare diseases or conditions4 7,b7 ,expiration ,subparagraph 7,a7 shall not apply with respect to any drug or biological product after the date on which such drug or biological product is approved or licensed by the ,food and ,drug ,administration for marketing for any indication other than the treatment of a rare disease or condition4 7,c7 ,rare disease or condition ,for purposes of this paragraph1 the term rare disease or condition has the meaning given such term under section #de;,c7d77#a7 of the ,internal ,revenue ,code of #aihf4 4 7b7 ,hold harmless for covered entities with no or limited orphan drug sales ,section #ijjh7;b7 of the ,patient ,protection and ,affordable ,care ,act is amended by adding at the end the following new paragraph3 7#e7 ,adjustment for certain covered entities with no or limited orphan drug sales ,if-- 7,a7 the fee under this section for a calendar year with respect to a covered entity 7determined without regard to this paragraph71 exceeds 7,b7 the fee that would be determined under this section for such year with respect to such entity if branded prescription drug sales of all covered entities were determined without regard to clauses 7ii7 and 7iii7 of subsection 7e77#c77;,a71 then such entity's fee under this section for such calendar year shall be determined as described in subparagraph 7,b74 4 7c7 ,effective date ,the amendments made by this section shall apply with respect to fees the annual payment date for which under section #ijjh of the ,patient ,protection and ,affordable ,care ,act is after ,december #ca1 #bjah4